Where should I publish my paper?
Paste your title, abstract or keywords. The finder matches them to research topics and suggests ranked journals that publish most on those topics.
Journals for “Lung Cancer Treatments and Mutations”
Suggested journals
Topic match is relative to the best match in this search (100% = best). Fees are shown only where DOAJ records them.
| # | Journal | Topic match | ITS Journal Score | Global rank | Papers 2021–2025 | Open access | Fee (APC) |
|---|---|---|---|---|---|---|---|
| 1 | Lung Cancer Targets and Therapy Dove Medical Press · New Zealand · DOAJ | 100% | 58.0 | #14,165 | 70 | 100% | US$3,940 |
| 2 | Clinical Lung Cancer Elsevier BV · United States | 87% | 73.3 | #5,020 | 849 | 41% | Not recorded |
| 3 | Journal of Thoracic Oncology Elsevier BV · United States | 83% | 74.8 | #4,212 | 10,750 | 61% | Not recorded |
| 4 | JTO Clinical and Research Reports Elsevier BV · United States · DOAJ | 85% | 64.1 | #10,305 | 679 | 100% | US$2,000 |
| 5 | Translational Lung Cancer Research AME Publishing Company · Hong Kong | 72% | 73.3 | #4,983 | 1,620 | 100% | Not recorded |
| 6 | Precision Cancer Medicine AME Publishing Company · Hong Kong | 78% | 54.8 | #16,215 | 128 | 82% | Not recorded |
| 7 | Lung Cancer Elsevier BV · The Netherlands | 67% | 74.7 | #4,262 | 3,096 | 25% | Not recorded |
| 8 | Thoracic Cancer Wiley · United Kingdom · DOAJ | 61% | 72.6 | #5,378 | 2,099 | 100% | US$3,180 |
| 9 | Targeted Oncology Adis, Springer Healthcare · France | 54% | 75.6 | #3,839 | 400 | 64% | Not recorded |
| 10 | Cancer Treatment and Research Communications Elsevier BV · United States · DOAJ | 58% | 62.9 | #11,104 | 757 | 100% | US$2,940 |
| 11 | Nature Reviews Clinical Oncology Nature Portfolio · United Kingdom | 38% | 93.3 | #89 | 646 | 20% | Not recorded |
| 12 | Journal of Cancer Research and Clinical Oncology Springer Science+Business Media · Germany · DOAJ | 41% | 82.5 | #1,369 | 2,893 | 100% | Not recorded |
| 13 | Annals of Oncology Elsevier BV · The Netherlands | 42% | 79.2 | #2,399 | 21,522 | 50% | Not recorded |
| 14 | The Lancet Oncology Elsevier BV · United Kingdom | 32% | 93.4 | #81 | 2,390 | 29% | Not recorded |
| 15 | Therapeutic Advances in Medical Oncology SAGE Publishing · United Kingdom · DOAJ | 41% | 76.7 | #3,432 | 1,043 | 100% | US$2,800 |
| 16 | Investigational New Drugs Springer Science+Business Media · The Netherlands | 40% | 77.4 | #3,116 | 555 | 39% | Not recorded |
| 17 | JCO Precision Oncology Lippincott Williams & Wilkins · United States | 41% | 75.2 | #4,028 | 1,263 | 68% | Not recorded |
| 18 | JAMA Oncology American Medical Association · United States | 34% | 88.1 | #417 | 1,919 | 50% | Not recorded |
| 19 | Journal of Clinical Oncology Lippincott Williams & Wilkins · United States | 37% | 80.9 | #1,861 | 39,012 | 32% | Not recorded |
| 20 | Clinical Medicine Insights Oncology SAGE Publishing · United Kingdom · DOAJ | 44% | 68.0 | #7,996 | 311 | 100% | US$2,650 |
| 21 | Future Oncology Future Medicine · United Kingdom | 38% | 77.1 | #3,250 | 1,741 | 68% | Not recorded |
| 22 | Cancer Research Statistics and Treatment Medknow · India · DOAJ | 46% | 61.0 | #12,311 | 931 | 100% | Not recorded |
| 23 | Journal of the National Comprehensive Cancer Network National Comprehensive Cancer | 33% | 84.3 | #971 | 1,951 | 38% | Not recorded |
| 24 | Journal of Molecular Pathology Multidisciplinary Digital Publishing Institute · Switzerland · DOAJ | 47% | 58.2 | #14,070 | 155 | 100% | 1,000 CHF |
| 25 | Chinese Clinical Oncology AME Publishing Company · Hong Kong | 44% | 63.0 | #11,047 | 426 | 100% | Not recorded |
| 26 | Cancer Research and Treatment Korean Cancer Association · South Korea | 38% | 74.6 | #4,335 | 660 | 100% | Not recorded |
| 27 | Oncology and Therapy Adis, Springer Healthcare · United Kingdom · DOAJ | 42% | 64.1 | #10,314 | 271 | 100% | 5,950 EUR |
| 28 | Cancer Discovery American Association for Cancer Research · United States | 28% | 89.0 | #329 | 2,477 | 46% | Not recorded |
| 29 | ESMO Open Elsevier BV · The Netherlands · DOAJ | 35% | 73.4 | #4,920 | 4,799 | 100% | US$4,310 |
| 30 | Expert Review of Anticancer Therapy Taylor & Francis · United Kingdom | 35% | 74.0 | #4,617 | 641 | 23% | Not recorded |
Before you submit
Use this list as a shortlist, not a decision. For each journal, read its aims and scope and a few recent articles, check its peer-review and fee policy on its own website, and confirm any indexing (Scopus, Web of Science, PubMed) with the indexer itself. Be careful with journals that promise very fast acceptance or that contact you by email asking for papers.
How the ITS Journal Score works
One formula applies to every ranked journal, using open data from OpenAlex: 45% citation impact, 35% h-index and 20% size (papers published 2021–2025). Citation impact is the smaller of the journal's two-year mean citedness and its five-year citations per paper, so a journal whose output collapsed cannot jump to the top on old citations. Each part is half a percentile and half a log-scaled value, so the very top is still separated. Growth and open-access share are shown separately and are not part of the score.
A journal is ranked only if it published at least 50 papers in 2021–2025 and was active in at least five of the last six years. Field rankings compare a journal only with journals in the same field; the field is the OpenAlex field with most of the journal's recent papers, or "Multidisciplinary" when no field has 30% of them.
What this is not: the ITS Journal Score is not a Journal Impact Factor, CiteScore or SJR, and this site does not say whether a journal is indexed in Scopus, Web of Science or PubMed. Always confirm aims and scope, indexing, peer review and fees on the journal's own website before you submit.